Expert Analysis

Clinical Pharmacology and Adverse Events

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Clinical Pharmacology and Adverse Events

Faculty:
Terrence F. Blaschke, MD Charles Boucher, MD, PhD William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 11/13/06

Expiration Date: 11/12/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review data related to pharmacokinetic interactions among antiretroviral agents
Discuss recommendations on how to safely discontinue nevirapine when stopping therapy
Recount data on adverse events associated with antiretroviral agents

Topics covered include:

Predictors of Response to Darunavir/Ritonavir
Pharmacokinetics of Etravirine Plus Darunavir/Ritonavir in Healthy Volunteers
Pharmacokinetic Interactions Between Brecanavir and Other PIs
DART Substudy: Pharmacokinetic Evaluation of Strategy for Discontinuation of Nevirapine
Risk of Nevirapine-Associated Toxicities in Developed and Developing Countries
Renal Impairment in HIV-Infected Patients in Africa on First-Line Treatment
Bioequivalence of a Soluble, Fixed-Dose Triple Combination Tablet With Potential for HIV-Infected Children

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.